Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-…
Market Outlook Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation…
Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market and thus is an attractive…
Osteoarthritic (OA) pain represents the second largest segment of the chronic pain market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. However, a…
DRG estimates that 60% of epilepsy patients experience partial-onset seizures (POS). More than two dozen antiepileptic drugs (AEDs) are available in the United States and Europe—the majority of…
Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia and a condition associated with extreme morbidity, mortality, and cost. The currently available AADs have…
The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo,…